Court Blocks Colorado's First-Ever Price Cap on Amgen's Enbrel

A U.S. federal judge has temporarily blocked Colorado's attempt to impose a price cap on Amgen's popular rheumatoid arthritis drug Enbrel. The ruling marks a significant development in a lawsuit challenging the state's first-of-its-kind drug pricing regulation. Colorado had enacted a law in 2023 authorizing the state to set price limits on certain high-cost drugs sold within its borders. Amgen sued, arguing the regulation violates federal law, and the court granted a temporary injunction in the company's favor. The judge noted that Colorado's price cap could negatively impact pharmaceutical companies' R&D investments and efforts to develop innovative drugs. The court also considered legal arguments regarding the state's limited authority to impose such regulations. This decision may influence other states pursuing similar drug pricing measures. Amgen maintains that Enbrel's price should be determined by market conditions and R&D costs. A final court ruling is expected in the coming months. This is not investment advice.